Yuzhiyou Biotech-B (02496) has announced that two clinical research findings related to its core innovative bispecific antibody product, M 701, have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Specifically, the Phase III clinical study results of M 701 for treating malignant ascites have been chosen for an oral presentation in the Clinical Science Symposium. Concurrently, the Phase II clinical research results for M 701 in the treatment of malignant pleural effusion have been selected for a poster presentation. This achievement marks another significant milestone for the M 701 project on the international oncology stage, demonstrating its continued recognition and attention from the global academic community in the treatment of malignant serous cavity effusions.